Treatment for Widespread Eczema (Atopic Dermatitis)
For widespread atopic dermatitis in adults, initiate systemic therapy with dupilumab (600 mg subcutaneously at initiation, then 300 mg every 2 weeks) alongside continued topical therapy, as this represents the strongest evidence-based first-line systemic agent with the best safety profile. 1, 2
Treatment Algorithm for Widespread Disease
Step 1: Confirm Inadequate Control with Optimized Topical Therapy
Before escalating to systemic therapy, ensure you have:
- Liberal moisturizer use (≥250 g per week for adults) 3
- Appropriate topical corticosteroids for active lesions
- Considered topical calcineurin inhibitors (tacrolimus, pimecrolimus) 4
- Ruled out alternative diagnoses like contact dermatitis or cutaneous lymphoma 2
If widespread disease persists despite optimized topicals, systemic therapy is indicated.
Step 2: First-Line Systemic Therapy - Dupilumab
Dupilumab is the unanimous first choice among guideline workgroup members and carries a strong recommendation from the 2024 AAD guidelines 2. This interleukin-4 receptor antagonist has:
- Established efficacy in large 52-week randomized trials
- Excellent safety track record over 5+ years in clinical practice
- No major emergent safety concerns
- No laboratory monitoring required before or during treatment 2
Dosing: 600 mg subcutaneously at initiation, followed by 300 mg every 2 weeks. After 16 weeks of adequate control, consider dose reduction to 300 mg every 4 weeks 2.
Common caveat: Conjunctivitis is a frequent side effect but manageable 2.
Step 3: Alternative Systemic Options if Dupilumab Fails or is Contraindicated
The 2025 focused update adds strong recommendations for newer agents 1:
Biologics (Strong Recommendations):
- Lebrikizumab (IL-13 inhibitor) - newly approved with strong recommendation 1
- Nemolizumab (IL-31 receptor inhibitor) - newly approved with strong recommendation, particularly effective for pruritus 1
- Tralokinumab (IL-13 inhibitor) - somewhat less effective than dupilumab at 16 weeks but safe alternative 2
JAK Inhibitors (Strong Recommendations):
- Upadacitinib, abrocitinib, or baricitinib - provide rapid relief of pruritus and inflammation 2, 5
- More rapid onset than biologics but carry greater safety considerations
- Require more careful patient selection due to safety profile 5
Traditional Immunosuppressants (Conditional Recommendations):
- Cyclosporine 3-5 mg/kg/day - effective but limited to 1 year use, requires monitoring 2
- Methotrexate, azathioprine, mycophenolate - conditional recommendations 2
Step 4: Maintain Concomitant Topical Therapy
Critical point: All systemic agents should be used WITH continued topical therapy, not as monotherapy 1, 2. Topicals serve for:
- Maintenance of response
- Rescue therapy
- Treatment of breakthrough flares
The 2025 guidelines specifically emphasize strong recommendations for using lebrikizumab and nemolizumab "with concomitant topical therapy" 1.
Step 5: Consider Phototherapy as Alternative
For patients who cannot access or tolerate systemic agents, narrowband UVB phototherapy receives a conditional recommendation 2. However, it requires:
- Multiple office visits per week
- Access to phototherapy equipment
- Less convenient than systemic options
What NOT to Use
Strong recommendation AGAINST systemic corticosteroids for chronic management 2. While they may provide temporary relief, they perpetuate the disease cycle and cause significant adverse effects.
Conditional recommendations AGAINST:
- Topical antimicrobials, antiseptics, and antihistamines for routine use 4
- Oral antihistamines do not reduce pruritus in AD 6
Practical Considerations
The choice between dupilumab and JAK inhibitors depends on:
- Speed needed: JAK inhibitors work faster for acute severe flares
- Safety profile: Dupilumab has fewer systemic safety concerns
- Comorbidities: Dupilumab improves asthma and eosinophilic esophagitis 5
- Patient preference: Injectable vs. oral administration
All guideline workgroup members surveyed favored dupilumab as first-line when systemic therapy is needed 2, making it the evidence-based default choice for widespread atopic dermatitis requiring systemic intervention.